588 related articles for article (PubMed ID: 34074219)
1. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab
Liu H; Wei P; Zhang Q; Chen Z; Aviszus K; Downing W; Peterson S; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G
MAbs; 2021; 13(1):1919285. PubMed ID: 34074219
[TBL] [Abstract][Full Text] [Related]
2. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Choudhary MC; Chew KW; Deo R; Flynn JP; Regan J; Crain CR; Moser C; Hughes MD; Ritz J; Ribeiro RM; Ke R; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Fletcher CV; Daar ES; Wohl DA; Eron JJ; Currier JS; Parikh UM; Sieg SF; Perelson AS; Coombs RW; Smith DM; Li JZ;
Nat Microbiol; 2022 Nov; 7(11):1906-1917. PubMed ID: 36289399
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Wibmer CK; Ayres F; Hermanus T; Madzivhandila M; Kgagudi P; Oosthuysen B; Lambson BE; de Oliveira T; Vermeulen M; van der Berg K; Rossouw T; Boswell M; Ueckermann V; Meiring S; von Gottberg A; Cohen C; Morris L; Bhiman JN; Moore PL
bioRxiv; 2021 Mar; ():. PubMed ID: 33501446
[TBL] [Abstract][Full Text] [Related]
4. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera.
Rathnasinghe R; Jangra S; Cupic A; Martínez-Romero C; Mulder LCF; Kehrer T; Yildiz S; Choi A; Mena I; De Vrieze J; Aslam S; Stadlbauer D; Meekins DA; McDowell CD; Balaraman V; Richt JA; De Geest BG; Miorin L; ; Krammer F; Simon V; García-Sastre A; Schotsaert M
medRxiv; 2021 Jan; ():. PubMed ID: 33501468
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Variants in Patients with Immunosuppression.
Corey L; Beyrer C; Cohen MS; Michael NL; Bedford T; Rolland M
N Engl J Med; 2021 Aug; 385(6):562-566. PubMed ID: 34347959
[No Abstract] [Full Text] [Related]
6. Descriptive Epidemiology of Travel and Non-Travel Related SARS-CoV-2 Gamma (P.1/501Y.V3) Variant Cases in England, 2021.
Abdul Aziz N; Twohig K; Sinnathamby M; Zaidi A; Aliabadi S; Groves N; Nash S; Thelwall S; Dabrera G
Influenza Other Respir Viruses; 2024 May; 18(5):e13308. PubMed ID: 38736251
[No Abstract] [Full Text] [Related]
7. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
[TBL] [Abstract][Full Text] [Related]
8. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Ku Z; Xie X; Hinton PR; Liu X; Ye X; Muruato AE; Ng DC; Biswas S; Zou J; Liu Y; Pandya D; Menachery VD; Rahman S; Cao YA; Deng H; Xiong W; Carlin KB; Liu J; Su H; Haanes EJ; Keyt BA; Zhang N; Carroll SF; Shi PY; An Z
Nature; 2021 Jul; 595(7869):718-723. PubMed ID: 34082438
[TBL] [Abstract][Full Text] [Related]
9. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
[TBL] [Abstract][Full Text] [Related]
10. Tackling COVID-19 with neutralizing monoclonal antibodies.
Corti D; Purcell LA; Snell G; Veesler D
Cell; 2021 Jun; 184(12):3086-3108. PubMed ID: 34087172
[TBL] [Abstract][Full Text] [Related]
11. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
[TBL] [Abstract][Full Text] [Related]
13. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
[TBL] [Abstract][Full Text] [Related]
14. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
[TBL] [Abstract][Full Text] [Related]
15. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y
Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.
Ryu DK; Song R; Kim M; Kim YI; Kim C; Kim JI; Kwon KS; Tijsma AS; Nuijten PM; van Baalen CA; Hermanus T; Kgagudi P; Moyo-Gwete T; Moore PL; Choi YK; Lee SY
Biochem Biophys Res Commun; 2021 Aug; 566():135-140. PubMed ID: 34119826
[TBL] [Abstract][Full Text] [Related]
18. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.
Caniels TG; Bontjer I; van der Straten K; Poniman M; Burger JA; Appelman B; Lavell AHA; Oomen M; Godeke GJ; Valle C; Mögling R; van Willigen HDG; Wynberg E; Schinkel M; van Vught LA; Guerra D; Snitselaar JL; Chaturbhuj DN; Martin IC; ; Moore JP; de Jong MD; Reusken C; Sikkens JJ; Bomers MK; de Bree GJ; van Gils MJ; Eggink D; Sanders RW
medRxiv; 2021 Jun; ():. PubMed ID: 34100023
[TBL] [Abstract][Full Text] [Related]
19. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.
Gu C; Cao X; Wang Z; Hu X; Yao Y; Zhou Y; Liu P; Liu X; Gao G; Hu X; Zhang Y; Chen Z; Gao L; Peng Y; Jia F; Shan C; Yu L; Liu K; Li N; Guo W; Jiang G; Min J; Zhang J; Yang L; Shi M; Hou T; Li Y; Liang W; Lu G; Yang C; Wang Y; Xia K; Xiao Z; Xue J; Huang X; Chen X; Ma H; Song D; Pan Z; Wang X; Guo H; Liang H; Yuan Z; Guan W; Deng SJ
MAbs; 2021; 13(1):1930636. PubMed ID: 34097570
[TBL] [Abstract][Full Text] [Related]
20. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch.
O'Toole Á; Hill V; Pybus OG; Watts A; Bogoch II; Khan K; Messina JP; ; ; ; Tegally H; Lessells RR; Giandhari J; Pillay S; Tumedi KA; Nyepetsi G; Kebabonye M; Matsheka M; Mine M; Tokajian S; Hassan H; Salloum T; Merhi G; Koweyes J; Geoghegan JL; de Ligt J; Ren X; Storey M; Freed NE; Pattabiraman C; Prasad P; Desai AS; Vasanthapuram R; Schulz TF; Steinbrück L; Stadler T; ; Parisi A; Bianco A; García de Viedma D; Buenestado-Serrano S; Borges V; Isidro J; Duarte S; Gomes JP; Zuckerman NS; Mandelboim M; Mor O; Seemann T; Arnott A; Draper J; Gall M; Rawlinson W; Deveson I; Schlebusch S; McMahon J; Leong L; Lim CK; Chironna M; Loconsole D; Bal A; Josset L; Holmes E; St George K; Lasek-Nesselquist E; Sikkema RS; Oude Munnink B; Koopmans M; Brytting M; Sudha Rani V; Pavani S; Smura T; Heim A; Kurkela S; Umair M; Salman M; Bartolini B; Rueca M; Drosten C; Wolff T; Silander O; Eggink D; Reusken C; Vennema H; Park A; Carrington C; Sahadeo N; Carr M; Gonzalez G; ; ; ; ; ; ; ; de Oliveira T; Faria N; Rambaut A; Kraemer MUG
Wellcome Open Res; 2021; 6():121. PubMed ID: 34095513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
